Kymera Therapeutics, Inc. SEC filings KYMR

Kymera Therapeutics, Inc. has 647 filings in SEC EDGAR's recent list, going back to Jun 22, 2020. Its latest annual report, Form ARS, was filed on Apr 29, 2026 for the period ended Dec 31, 2025. The latest quarterly report (Form 10-Q) was filed on Oct 29, 2026, covering the quarter ended Sep 30, 2026. The most recent current report (Form 8-K) was filed on Oct 29, 2026 (results of operations). The company's fiscal year ends on December 31.

Form Description Filed Period
ARS Annual report to shareholders Apr 29, 2026 Dec 31, 2025
10-K Annual report Feb 26, 2026 Dec 31, 2025
ARS Annual report to shareholders Apr 29, 2025 Dec 31, 2024
10-K Annual report Feb 27, 2025 Dec 31, 2024
ARS Annual report to shareholders Apr 24, 2024 Dec 31, 2023
10-K Annual report Feb 22, 2024 Dec 31, 2023
ARS Annual report to shareholders Apr 27, 2023 Dec 31, 2022
10-K Annual report Feb 23, 2023 Dec 31, 2022
10-K Annual report Feb 24, 2022 Dec 31, 2021
10-K Annual report Mar 11, 2021 Dec 31, 2020

Showing 10 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.

New to this? Read What Are SEC Filings? 10-K, 10-Q, 8-K and Other Forms Explained.

Company profile

Industry
Biological Products, (No Diagnostic Substances) (SIC 2836)
Listed as
KYMR (Nasdaq)
Fiscal year ends
December 31
Incorporated in
DE
Headquarters
Watertown, MA
SEC filer status
Large accelerated filer
SEC CIK
1815442
Former names
Kymera Therapeutics, Inc. (until Oct 29, 2026)

Other Biological Products, (No Diagnostic Substances) companies

All 182 Biological Products, (No Diagnostic Substances) companies

Source: SEC EDGAR filings. This is company-reported data, not investment advice.